On August 27, 2026, Morgan Stanley bought 2.77 million shares of PHARMARON (H shares) at an average of HKD 29.6166 per share, involving about HKD 81.90 million.
Prior to the acquisition, Morgan Stanley's long position in PHARMARON was 17.74 million shares, representing 4.95%; following the acquisition, the holding changed to 20.51 million shares, with the long position ratio rising to 5.69%.